Durable Response of Pembrolizumab for EGFR Mutation-positive Lung Adenocarcinoma with Early Progression to Osimertinib in First-line Treatment

Overview

Journal Intern Med

Specialty General Medicine

Date 2024 Jul 10

PMID 38987188

Authors

Aoi Miyazaki

Koichi Saruwatari

Toru Yamanaka

Kenji Shiraishi

Yusuke Tomita

Hidenori Ichiyasu

Takuro Sakagami

Affiliations

Soon will be listed here.

Abstract

Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, is the standard first-line treatment for EGFR mutation-positive non-small-cell lung cancer (NSCLC) and demonstrates favorable disease control. Conversely, immune checkpoint inhibitors (ICIs) that target programmed cell death-1/programmed cell death ligands demonstrate a restrictive tumor response. We herein report a patient who achieved a durable response to pembrolizumab following early progression within two months of osimertinib administration for EGFR mutation-positive lung adenocarcinoma. Our findings suggest that treatment with ICIs for patients with EGFR mutation-positive NSCLC experiencing early progression to osimertinib as first-line treatment might represent a viable approach.

References

Attili I, Passaro A, Corvaja C, Trillo Aliaga P, Del Signore E, Spitaleri G . Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review. Cancer Treat Rev. 2023; 119:102602. DOI: 10.1016/j.ctrv.2023.102602. View

Peters S, Kerr K, Stahel R . PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. Cancer Treat Rev. 2017; 62:39-49. DOI: 10.1016/j.ctrv.2017.10.002. View

Sakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R . Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT). Eur J Cancer. 2021; 159:144-153. DOI: 10.1016/j.ejca.2021.09.041. View

Soria J, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee K . Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 378(2):113-125. DOI: 10.1056/NEJMoa1713137. View

Ramalingam S, Vansteenkiste J, Planchard D, Cho B, Gray J, Ohe Y . Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC. N Engl J Med. 2019; 382(1):41-50. DOI: 10.1056/NEJMoa1913662. View

Hendriks L, Kerr K, Menis J, Mok T, Nestle U, Passaro A . Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34(4):339-357. DOI: 10.1016/j.annonc.2022.12.009. View

Hanna N, Robinson A, Temin S, Baker Jr S, Brahmer J, Ellis P . Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. J Clin Oncol. 2021; 39(9):1040-1091. DOI: 10.1200/JCO.20.03570. View

Hastings K, Yu H, Wei W, Sanchez-Vega F, DeVeaux M, Choi J . EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. Ann Oncol. 2019; 30(8):1311-1320. PMC: 6683857. DOI: 10.1093/annonc/mdz141. View

Johnson M, Garassino M, Mok T, Mitsudomi T . Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. Lung Cancer. 2022; 170:41-51. DOI: 10.1016/j.lungcan.2022.05.011. View

10.

Chen Q, Shang X, Liu N, Ma X, Han W, Wang X . Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors. Front Immunol. 2022; 13:931718. PMC: 9388930. DOI: 10.3389/fimmu.2022.931718. View

11.

Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li B . Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with -Mutant Lung Cancers. Clin Cancer Res. 2018; 25(3):1063-1069. PMC: 6347551. DOI: 10.1158/1078-0432.CCR-18-1102. View

12.

Hsu K, Tseng J, Yang T, Chen K, Su K, Yu S . PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. Sci Rep. 2022; 12(1):9753. PMC: 9192769. DOI: 10.1038/s41598-022-13102-7. View

13.

Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y . The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Int J Clin Oncol. 2019; 24(7):731-770. PMC: 6545178. DOI: 10.1007/s10147-019-01431-z. View

14.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

15.

Ichihara E, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D . Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors. Cancer Immunol Immunother. 2020; 70(1):101-106. PMC: 10991645. DOI: 10.1007/s00262-020-02662-0. View

16.

Ferro A, Marinato G, Mulargiu C, Marino M, Pasello G, Guarneri V . The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies. Crit Rev Oncol Hematol. 2024; 196:104295. DOI: 10.1016/j.critrevonc.2024.104295. View

17.

Zhang Y, Zeng Y, Liu T, Du W, Zhu J, Liu Z . The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer. Respir Res. 2019; 20(1):164. PMC: 6647099. DOI: 10.1186/s12931-019-1137-4. View

18.

Liu S, Wu F, Li X, Zhao C, Jia Y, Jia K . Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC. Front Oncol. 2021; 11:639947. PMC: 7991800. DOI: 10.3389/fonc.2021.639947. View